August 17, 2026 at 07:04 AM 2 min readmarketsbreaking
Dhoot Transmission and Molbio Diagnostics Make Strong Stock Market Debuts
Dhoot Transmission Listing:
Dhoot Transmission made a strong stock market debut on Monday, August 17, 2026, with shares listing at a premium of approximately 38% over the issue price of ₹871. On the NSE, the shares opened at ₹1,200, marking a 37.77% increase, while on the BSE, they debuted at ₹1,193.80, a 37.06% premium.
Molbio Diagnostics IPO:
Molbio Diagnostics also experienced a robust listing on August 17, 2026, with its shares debuting at ₹980 on both the NSE and BSE, representing a 21.44% premium over its issue price of ₹807. The company raised ₹939.70 crore through the IPO, which was subscribed 70.26 times overall.
Market Impact:
The successful market debuts defy broader weak stock market sentiment, highlighting strong investor appetite for well-positioned diagnostics and manufacturing firms. Pramodini Medicare's IPO allotment was also finalized on August 17, with shares slated to list on the NSE SME platform on August 19, 2026.
Pulse Intelligence
Context & ImpactContext & Background
- Dhoot Transmission raised ₹3,067 crore through a combination of fresh shares and an offer for sale, with backing from institutional investors.
- Molbio Diagnostics reported a 42% year-on-year increase in total income for FY26, reaching ₹1,455 crore.
Key Consequences
- Investors who secured shares in Dhoot Transmission and Molbio Diagnostics record strong initial listing gains.
- Molbio Diagnostics will deploy IPO proceeds to build an R&D facility and a Centre of Excellence.
Market & Economic Impact
Strong listings provide a boost to primary market activity despite broader benchmark volatility.
The Indus Pulse is committed to accuracy and transparency.